

COM-2024-058

02
SEPTEMBER
2024

PLEASE REVIEW Drug Information

PharmPix Clinical Department

Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

QUESTIONS

Call us at 787-522-5252-ext 219

Access our recent communications at our providers' portal:
<https://www.pharmpix.com/providers/>.



PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information requested.

First Nasal Spray for Treatment of Anaphylaxis

In August 2024, the U.S. Food and Drug Administration (FDA) approved Neffy™ (epinephrine nasal spray) as the first non-injection-based treatment for anaphylaxis, a severe and potentially life-threatening allergic reaction. This groundbreaking approval allows both adult and pediatric patients weighing at least 66 pounds to use Neffy™ for emergency treatment.

Background

Anaphylaxis is a severe allergic reaction that can involve multiple body systems and is considered a medical emergency. Common triggers include certain foods, medications, and insect stings. Symptoms can include hives, swelling, itching, difficulty breathing, and loss of consciousness. Epinephrine is the only life-saving treatment for this condition.

The first epinephrine nasal spray

Neffy™, the first nasal spray for the treatment of anaphylaxis, was approved with the support of four clinical studies, which included 175 healthy adults without anaphylaxis. These studies showed that epinephrine levels in the blood after using Neffy™ were comparable to those from traditional epinephrine injections. Additionally, Neffy™ demonstrated similar effects on blood pressure and heart rate.

Neffy™ is administered as a single dose nasal spray into one nostril. A second dose may be used if symptoms do not improve or worsen, but patients should seek emergency medical help for further treatment and monitoring. Some of the common side effects include throat irritation, nasal discomfort, headache, jitteriness, and nausea.

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext. 219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

PharmPix Drug Information Communication Number COM-2024-058 September 2024



REFERENCES: <<APA FORMAT>>

1. Lutton, L. (2024, August 9). Nasal Spray for Treatment of Anaphylaxis Approved by FDA. *Managed Healthcare Executive*. <https://www.managedhealthcareexecutive.com/view/nasal-spray-for-treatment-of-anaphylaxis-approved-by-fda>
2. FDA. (2024, August 9). FDA Approves First Nasal Spray for Treatment of Anaphylaxis. U.S. Food and Drug Administration. [https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis#:~:text=Today%2C%20the%20U.S.%20Food%20and%20kilograms%20\(about%2066%20pounds\).](https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis#:~:text=Today%2C%20the%20U.S.%20Food%20and%20kilograms%20(about%2066%20pounds).)
3. Neffy® (epinephrine nasal spray) | Serious Allergic Reactions. (n.d.). <https://neffy.com/>



2 Street 1, Suite 500
Guaynabo, PR 00968

Tel. 787.522.5252
Fax 866.912.2830

www.pharmpix.com
FRM-CL-000130-001

